Spectral to sell Toraymyxin in Canada

Spectral Diagnostics (TSX:SDI) has signed a long-term, exclusive distribution agreement with Toray Industries and Toray Medical of Japan to market and sell in Canada Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. The product and Spectral’s EAA diagnostic, which measures endotoxin and identifies patients for treatment, are already [...]

Spectral starts U.S. trial of Toraymyxin

Spectral Diagnostics (TSX:SDI) has initiated its U.S. pivotal trial of Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis. The EUPHRATES trial will study standard of care versus standard of care and Toraymyxin directed by Spectral’s Endotoxin Activity Assay (EAA), an FDA cleared assay for use in sepsis. [...]

Riding the Next Wave

No, we’re not talking about the north coast of Maui but rather a new research platform from long-time biotech analyst David Martin of Dundee Securities. “If I’m going to recommend that investors own a basket of biotech stocks, it makes sense that I ought to initiate on a basket of stocks rather than make one-off [...]